Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 5NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Carcinoma, Intraductal, Noninfiltrating 2Inflammatory Breast Neoplasms 1Breast Carcinoma In Situ 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Tamoxifen 5Specimen Handling 4Radiotherapy 3Chemotherapy, Adjuvant 2Biopsy 2pembrolizumab 1exemestane 1Watchful Waiting 1Therapeutics 1Sulindac 1Radiation 1Psychiatric Rehabilitation 1Omacor 1Observation 1Norethindrone Acetate 1Neoadjuvant Therapy 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Letrozole 1Hypnosis 1High-Energy Shock Waves 1Gene Expression Profiling 1Fulvestrant 1Estradiol 1Early Intervention, Educational 1Docosahexaenoic Acids 1Bexarotene 1Atorvastatin 1Anastrozole 1Analgesia 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Carcinoma In Situ × Anastrozole × Clear all
NCT00077168 2009-02-09

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

National Cancer Institute (NCI)

Phase 2 Unknown
2,000 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡